Oligomycin Complex |
Catalog No.GC16533
One-Click Copy Product Info
|
Oligomycin complex consists of a blend of oligomycins A, B, and C.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1404-19-9
Sample solution is provided at 25 µL, 10mM.
Oligomycin complex consists of a blend of oligomycins A, B, and C. Oligomycin is a class of similar 26-membered macrolide antibiotics isolated from Streptomyces amylase chromogenes. Oligomycin has antifungal activity, oxidative phosphorylation inhibition and insecticidal activity[1].Oligomycin A primarily exerts its inhibitory effect on mitochondrial oxidative phosphorylation by blocking the proton channel (F0 subunit) of ATP synthase, thus inhibiting ATP synthesis. Additionally, it reduces the compensatory increase in oxidative phosphorylation in tumor cells, leading to a decrease in cellular glycolysis levels[2-4].Oligomycin B acts as a non-selective inhibitor of ATP synthases, effectively slowing down ATP depletion in cases of myocardial ischemia. Oligomycin C is an inhibitor of mitochondrial F1F0-ATP synthase, which induces more sensitive cell death and shifts the cell death pattern from apoptosis to necrosis.
Oligomycin(0-50µg/ml; 24h) induced mitochondrial membrane depolarization and cytochrome c release in HepG2 and R-HepG2 cells[5].Oligomycin A(0-16 µM;12-48 h) promotes HT29 cell survival and proliferation[6]. In A549 cells, 100 ng/ml Oligomycin could completely inhibit OXPHOS phosphorylation activity in 1 hour and stimulate various levels of glycolysis gains[7]. 5 µg/ml Oligomycin could inhibit the F0 part of H+-ATP-synthase, and strongly suppress cytochrome c release and apoptosis in Hela cells induced by TNF[8]. Oligomycin B(1 µM) induced vasodilations that were 39-61% smaller in sulfonylurea receptor 2 null (SUR2(nl)) than in SUR2 wild-type (SUR2(wt)) arteries[9].
References:
[1]. SMITH RM, PETERSON WH, et,al.Oligomycin, a new antifungal antibiotic. Antibiot Chemother (Northfield). 1954 Sep;4(9):962-70. PMID: 24543225.
[2]. Vestergaard M, NØhr-Meldgaard K, et al. Inhibition of the ATP synthase eliminates the intrinsic resistance of Staphylococcus aureustowards polymyxins[J].mBio, 2017, 8(5): e01114-17.
[3]. Untereiner AA, Pavlidou A, et al. Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells[J].Biochem Pharmacol, 2018, 149: 174-185.
[4]. Ruas JS, Siqueira-Santos ES, et al. High glycolytic activity of tumor cells leads to underestimation of electron transport system capacity when mitochondrial ATP synthase is inhibited[J].Sci Rep, 2018, 8(1): 17383.
[5]. Li YC, Fung KP, et,al. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. doi: 10.1159/000077803. PMID: 15211078.
[6]. Li X, Tian R, et,al. Oligomycin A promotes radioresistance in HT29 colorectal cancer cells and its mechanisms. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Feb 28;46(2):113-120. English, Chinese. doi: 10.11817/j.issn.1672-7347.2021.200063. PMID: 33678646.
[7]. Hao W, Chang CP, et al. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J Biol Chem. 2010 Apr 23;285(17):12647-54. doi: 10.1074/jbc.M109.084194. Epub 2010 Jan 28. PMID: 20110356; PMCID: PMC2857128.
[8]. Shchepina LA, Pletjushkina OY, et al. Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene. 2002 Nov 21;21(53):8149-57. doi: 10.1038/sj.onc.1206053. PMID: 12444550.
[9]. Adebiyi A, McNally EM, et al. Vasodilation induced by oxygen/glucose deprivation is attenuated in cerebral arteries of SUR2 null mice. Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1360-8. doi: 10.1152/ajpheart.00406.2011. Epub 2011 Jul 22. PMID: 21784985; PMCID: PMC3197357.
|
Cell experiment 1 [1]: |
|
|
Cell lines |
R-HepG2 and HepG2 cells |
|
Preparation method |
Cells were treated with oligomycin at the concentration indicated or medium alone at 37°C, 5% CO2 for 24 h. |
|
Reaction Conditions |
0-50μg/ml; 24h |
|
Applications |
Oligomycin induced mitochondrial depolarization in R-HepG2 and HepG2 cells. |
|
Cell experiment 2 [2]: |
|
|
Cell lines |
HT29 cell |
|
Preparation method |
Cells were cultured with different concentrations of oligomycin A for 12,24,36 and 48 h. |
|
Reaction Conditions |
0-16 μM;12-48 h |
|
Applications |
Oligomycin promotes HT29 cell survival and proliferation. |
|
References: [1]. Li YC, Fung KP, et,al. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. doi: 10.1159/000077803. PMID: 15211078. [2]. Li X, Tian R, et,al. Oligomycin A promotes radioresistance in HT29 colorectal cancer cells and its mechanisms. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Feb 28;46(2):113-120. English, Chinese. doi: 10.11817/j.issn.1672-7347.2021.200063. PMID: 33678646. |
|
| Cas No. | 1404-19-9 | SDF | |
| Canonical SMILES | O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H](C/C=C/C=C/[C@]([H])(CC[C@@]1([C@@H]([C@]([H])(O2)[C@H]([C@@]3(O1)C(C[C@H]([C@]([H])(O3)C[C@H](C)O)C)=O)C)C)[H])CC)C)O)O)=O)C)O)C)[C@@H]([C@H]([C@@H](/C=C/C2=O)C)O)C.O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H | ||
| Formula | C45H74O11 for Oligomycin A; C45H72O12 for Oligomycin B; C45H74O10 for Oligomycin C. | M.Wt | 791.06 for Oligomycin A; 805.1 for Oligomycin B; 775.1 for Oligomycin C. |
| Solubility | ≤30mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2641 mL | 6.3206 mL | 12.6413 mL |
| 5 mM | 252.8 μL | 1.2641 mL | 2.5283 mL |
| 10 mM | 126.4 μL | 632.1 μL | 1.2641 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)